Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 95.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 225 shares of the company’s stock after acquiring an additional 110 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Medpace were worth $93,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Cim LLC purchased a new position in shares of Medpace during the 4th quarter worth approximately $2,436,000. Vima LLC purchased a new position in Medpace in the fourth quarter worth $54,000. Congress Asset Management Co. MA lifted its holdings in Medpace by 3.9% in the fourth quarter. Congress Asset Management Co. MA now owns 153,394 shares of the company’s stock valued at $47,020,000 after acquiring an additional 5,819 shares during the period. Vanguard Group Inc. boosted its position in shares of Medpace by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after purchasing an additional 142,591 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Medpace by 5.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,750 shares of the company’s stock worth $2,682,000 after purchasing an additional 488 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the subject of several recent analyst reports. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. TD Cowen decreased their price target on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Truist Financial started coverage on Medpace in a research report on Thursday, August 1st. They set a “hold” rating and a $415.00 target price on the stock. Finally, William Blair restated an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.00.

Medpace Trading Up 0.9 %

Shares of MEDP stock opened at $347.91 on Friday. The company has a market capitalization of $10.79 billion, a price-to-earnings ratio of 32.83, a PEG ratio of 1.77 and a beta of 1.35. The firm has a 50-day moving average price of $359.84 and a 200 day moving average price of $385.68. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.93 earnings per share. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.64 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.